Tukon Indications/Uses

Amlodipine is indicated in patients with essential hypertension: Prevention of cardiovascular disease in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease; Reduce the risk of myocardial infarction; Reduce the risk of stroke; Reduce the risk for revascularization procedures and angina in patients with type-2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension.
Atorvastatin is indicated to: Reduce the risk of myocardial infarction; Reduce the risk of stroke in patients with clinically evident coronary heart disease; Reduce the risk of non-fatal myocardial infarction; Reduce the risk of fatal and non-fatal stroke; Reduce the risk for revascularization procedures; Reduce the risk of angina; Reduce the risk of hospitalization for CHF.
As adjunct therapy to diet for reducing elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with: Primary hypercholesterolemia (heterozygous familial and nonfamilial); Mixed dyslipidemia (Fredrickson Types IIa and IIb); Elevated serum triglyceride levels (Fredrickson Type IV); Primary dysbetalipoproteinemia (Fredrickson Type III).
To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments.
As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remain ≥190 mg/dL or LDL-C remain ≥160 mg/dL, and there is a positive family history of premature cardiovascular disease; or two or more other CVD risk factors are present in the pediatric patient therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia.